References
- Chang M, Chow SC, Pong A. Adaptive design in clinical research: Issues, opportunities, and recommendations. Journal of Biopharm Stat 2006; 16: 299–309
- Cummings JL. Measuring disease modification in Alzheimer's disease. CNS Spectr 2007; 12: 11–14
- Cummings J, Doody M, Clark C. Disease-modifying therapies for Alzheimer disease. Neurology 2007; 69
- Doniger G, Dwolatzky T, Zucker DM, et al. Computerized cognitive testing battery identifies mild cognitive impairment and mild dementia even in the presence of depressive symptoms. American Journal of Alzheimer's Disease 2006; 21: 28–36
- Dubois B, Jacova J, DeKosky J, et al. Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS–ADRDA criteria. Lancet Neurology 2007; 6: 734–746
- Engler H, Forsperg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; 129: 2856–2866
- European Medicines Agency. Guideline on medicinal products for the treatment of Alzheimer's disease and other dementias. CPMP/EWP/553/95 Rev., European Medicines Agency, London 2007
- Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 2007; 64: 1323–1329
- Hendrix S, Gutin A, Zavitz K, Carron G, Laughlin M, Horton S. Modification of the staggered start and randomized withdrawal clinical trial designs: Toward a practical demonstration of disease modification in Alzheimer's disease. Alzheimer's and Dementia 2007; 3: S160
- Jack JCR, Petersen RC. Structural imaging approaches to Alzheimer's Disease. Early diagnosis of Alzheimer's disease, FM Scinto, KR Daffner. Humana Press Inc, Totowa, NJ 2000
- Katz R. Biomarkers and surrogate markers: An FDA perspective. NeuroRx 2004; 1: 189–195
- Mani RB. The evaluation of disease modifying therapies in Alzheimer's disease: A regulatory viewpoint. Stat Med 2004; 23: 305–314
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939–944
- Mohs RC, Kawas C, Carrillo MC. Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease. Alzheimer's and Dementia 2006; 2: 131–139
- Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985–1992
- Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine 2005; 352: 2379–2388
- Rang H. Drug discovery and development–Facts and figures. Churchill Livingstone Elsevier, London 2006
- Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. American Journal of Psychiatry 1984; 141: 1356–1364
- Sampaio C. Alzheimer disease: Disease modifying trials–Where are we? Where do we need to go? A reflective paper. Journal of Nutrition, Health & Aging 2006; 10: 113–115
- Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. New England Journal of Medicine 1997; 336: 1216–1222
- Verheijen J, Huisman L, van Lent N, et al. Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clinical Chemistry 2006; 52: 1168–1174
- Wang SJ, Hung HMJ, Tsong Y, Cui L. Group sequential test strategies for superiority and non-inferiority hypotheses in active controlled clinical trials. Stat Med 2001; 20: 903–1912